Erythropoietin (EPO), in addition to its hematopoietic functions, demonstrates non-hematopoietic functions such as anti-apoptotic, anti-inflammatory, and antioxidant properties. The EPO effect was confirmed to be tissue-protective in the context of myocardium, brain, kidney, and liver injuries. Mesenchymal stem cells (MSCs) are non-hematopoietic cells. It can be extracted from the dental pulp, bone marrow, placenta, adipose tissue, amniotic membrane, or umbilical cord. MSCs have the potential to repair damaged tissues of the liver, enhance liver functions, and decrease fibrosis of the liver, as evidenced by preclinical and clinical research studies. Materials and Methods: Eleven equal groups were created from sixty-six mature male albino rats. There were some biochemical investigations conducted on blood samples, and histological Masson studies were assessed in the liver tissue. Results: The toxic effect of GalN was mitigated by MSCs and EPO treatment, resulting in a substantial reduction in the mean levels of AST, ALT, and total bilirubin and alkaline phosphate, an improvement in albumin level, and histological studies. The protection against GalN toxicity was more efficacious when MSCs and EPO were combined.